|Bid||1.3600 x 4000|
|Ask||1.3700 x 3000|
|Day's Range||1.3500 - 1.4000|
|52 Week Range||1.0100 - 2.1400|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 05, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.80|
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Geron Corporation (“Geron” or the “Company”) (GERN) in the United States District Court for the Northern District of California on behalf of those who purchased or acquired the securities of Geron between March 19, 2018 and September 26, 2018, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Geron investors under the federal securities laws.
NEW YORK, NY / ACCESSWIRE / January 24, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a ...
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Geron Corporation Investors
NEW YORK, NY / ACCESSWIRE / January 24, 2020 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Geron Corporation ("Geron" or the Company") ...
NEW YORK, NY / ACCESSWIRE / January 24, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. ...
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Geron Corporation.
NEW YORK, NY / ACCESSWIRE / January 24, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ...
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Geron Corporation (NASDAQ: GERN) between March 19, 2018 and September 26, 2018, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Geron investors under the federal securities laws.
Johnson Fistel, LLP announces that it has filed a class action lawsuit on behalf of all those who purchased or otherwise acquired Geron Corporation ("Geron") (NASDAQ: GERN) common stock during the period between March 19, 2018 and September 26, 2018, inclusive (the "Class Period"). This action was filed in the United States District Court for the Northern District of California, case No. 3:20-cv-00547
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 98,000 shares of Geron common stock as inducements to two newly-hired employees in connection with commencement of employment with the Company.
Geron Corporation (Nasdaq: GERN), a late-stage clinical development biopharmaceutical company, today announced 2019 accomplishments and key development priorities for 2020. The Company is currently enrolling patients in the Phase 3 IMerge clinical trial of imetelstat in lower risk myelodysplastic syndromes (MDS), and plans to complete enrollment by the end of 2020 with top-line results expected by mid-year 2022.
Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 100,000 shares of Geron common stock as an inducement to a newly-hired employee in connection with commencement of employment with the Company.
Geron Corporation (Nasdaq: GERN) today announced that the Company has conducted an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to discuss the results of the IMbark Phase 2 clinical trial of imetelstat in patients with Intermediate-2 or High-risk myelofibrosis (MF) whose disease has relapsed after or is refractory to janus kinase (JAK) inhibitor treatment, or relapsed/refractory MF. Based on feedback from the meeting, over the coming months Geron plans to submit several Phase 3 trial design proposals in relapsed/refractory MF and to have further discussions with the FDA regarding potential regulatory approval pathways. The Phase 3 trial proposals will be designed to fully characterize the efficacy, safety, and benefit-risk profile of imetelstat treatment for these patients, as well as to confirm the clinical benefit and disease-modifying potential of imetelstat in this indication. Subsequent to these additional discussions with the FDA, and after considering the timing and resources required, as well as other clinical development opportunities for imetelstat, Geron will make a decision regarding potential late-stage development of imetelstat in relapsed/refractory MF.
The FDA bestows a Breakthrough Therapy status on Agios' (AGIO) leukemia drug Tibsovo for treating relapsed/refractory myelodysplastic syndrome in adult patients with a susceptible IDH1 mutation.
Geron Corporation (Nasdaq: GERN) today announced that two posters related to imetelstat, the Company’s first-in-class telomerase inhibitor, were presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida on December 8 and 9. Both posters are available on Geron’s website at www.geron.com/r-d/publications.
Biotech stocks went back and forth but managed to end the week with a gain. As usual, some stocks swung wildly in reaction to catalysts, primarily clinical readouts. Aurinia Pharmaceuticals Inc (NASDAQ: ...
Geron Corporation (GERN) today announced the appointment of Anil Kapur as Executive Vice President, Corporate Strategy and Chief Commercial Officer. “We are pleased to welcome Anil whose proven track record in shaping hematology-oncology development programs, launching blockbuster oncology products and managing external alliances rounds out our executive team’s capabilities,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer.
Geron's (GERN) telomerase inhibitor, imetelstat, is being evaluated in two clinical studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.
Geron Corporation (GERN) today reported financial results for the third quarter and year-to-date as of September 30, 2019 as well as recent events. The Company ended the third quarter with $159.3 million in cash and marketable securities. “Geron has continued to execute on its 2019 development plans,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer.
MENLO PARK, Calif., Nov. 06, 2019 -- Geron Corporation (Nasdaq: GERN) today announced that two abstracts related to imetelstat, the Company’s first-in-class telomerase.